NAB Shares Hit Record High as First-Quarter Cash Earnings Jump 16% 
Anthropic’s Claude AI Reportedly Used in U.S. Operation to Capture Nicolas Maduro 
Goldman Sachs Reportedly Drops Diversity Criteria From Board Candidate Evaluations 
AstroTurf Expands Footprint at Colorado as Buffaloes Complete Second Installation in 12 Months 
Stock Market Movers: NVIDIA and Meta Expand AI Partnership as Cadence Surges on Earnings 
Thomas Pritzker to Step Down as Hyatt Executive Chairman After Epstein Ties Acknowledged 
BlueScope Steel Forecasts Stronger Second-Half Earnings, Shares Rise Above Rejected Buyout Offer 
Federal Court Fines Mobil Oil Australia A$16 Million for Misleading Fuel Claims 
Luxury Stocks Face Volatility as AI Market Swings and Hedge Fund Bets Rattle LVMH and Kering 
Starboard Value Targets Tripadvisor Board Overhaul Amid Stock Slump 
India AI Impact Summit 2026: Global Tech CEOs Join World Leaders in New Delhi 
Hedge Funds Cut Nvidia, Amazon and Microsoft Stakes as AI Valuation Concerns Rise 
European IT Hardware Stocks to Watch as Gaming Demand Outpaces Smartphones, Says BofA 
Freedom Finance and Binance Join Forces in Digital Assets 
Treasury Wine Estates Profit Falls 46% as China and U.S. Inventory Reset Weighs on Earnings 
Anduril Industries Seeks $8 Billion Funding at $60 Billion Valuation 
Santos Wins Court Case Over Net Zero and Sustainability Claims 
MORRISTOWN, N.J., May 01, 2018 -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, announced today that the Company will report financial results for the first quarter ended March 31, 2018, after the market close on Thursday, May 10, 2018. Pernix management will also host a conference call at 4:30pm Eastern Time to discuss the results.
| Date: | Thursday, May 10 | ||||||||
| Time: | 4:30 PM ET | ||||||||
| Toll free (U.S.): | 888-394-8218 | ||||||||
| International: | 323-701-0225 | ||||||||
| Conference ID: | 7026871 | ||||||||
| Webcast: | http://public.viavid.com/index.php?id=129150 | ||||||||
About Pernix Therapeutics
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company is currently focused on the therapeutic areas of Pain and Neurology, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its internal sales force and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc.
To learn more about Pernix Therapeutics, visit www.pernixtx.com.
CONTACT
Investor Relations
Bob Yedid
LifeSci Advisors, LLC
[email protected]
